Vanda Pharmaceuticals has another suitor
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Well, this wraps up one of the most eventful weeks of the biotech year — ASCO, followed by BIO. Anyone else as zonked as I am? Today, we discuss the impact that the BIOSECURE Act is already having on the industry, preview what FDA reviewers want to know about donanemab, and more.
Read Original Article: Vanda Pharmaceuticals has another suitor »
